Menu Search
Equities

Canntab Therapeutics Ltd

TBF1:MUN

Canntab Therapeutics Ltd

Actions
  • Price (EUR)0.007
  • Today's Change0.00 / 0.00%
  • Shares traded5.50k
  • 1 Year change+1,300.00%
  • Beta--
Data delayed at least 15 minutes, as of Oct 06 2023 08:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company’s operations comprise a single segment engaged in the medical marijuana business. The Company’s hard pill cannabinoid formulations provide doctors, patients, and consumers with medical grade solutions. These include once a day and extended-release formulations. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet (ODT). The IR Tablet is a release profile for solid hard tablets. The XR Tablet is a phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. ODT is specifically designed to dissolve directly in the patient’s mouth, with an onset of action between five and thirty minutes.

  • Revenue in CAD (TTM)73.48k
  • Net income in CAD-3.36m
  • Incorporated2021
  • Employees--
  • Location
    Canntab Therapeutics Ltd411 Cranbrooke AvenueTORONTO M4M 1N4CanadaCAN
  • Websitehttps://canntab.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.